Roche Menu Search Global Web Site : About Roche Roche in your country Language: Deutsch Contact Search Search Roche Sprache: DE Worldwide Deutsch Contact Home About Roche Products Sustainability Research & Development Partnering Media Investors Careers Roche in your Country Contact Our purpose Our history Our business priorities Our business Our people Our governance What is Roche Personalised Healthcare all about? You are here: About Roche Our business priorities What is Roche Personalised Healthcare all about? What is Roche Personalised Healthcare all about? It is more important to know what sort of person has a disease than what sort of disease a person has. Hippocrates Personalised Healthcare (PHC) is about providing the right treatment for the right group of patients. Roche’s strengths in pharmaceuticals and diagnostics along with advances in science and technology have made fitting treatments to patients possible. Did you know that previously, only five out of ten patients, on average, actually benefited from their treatment? Today, up to 80% of patients respond to their targeted therapies. How does PHC work? Before PHC After PHC Before PHC After PHC From better disease understanding to supporting regulatory approvals Helps to determine the malfunction in the body. Employing diagnostic tests like liquid biopsy help to find the specific genetic defects or biomarkers in the patients’ tissue to understand the molecular root cause of the disease. Allows scientists to distinguish between different patient sub-groups as one disease may have different, multiple causes. Supports the development of targeted molecules. Supports recruitment of relevant patients for clinical studies. Helps to identify biomarkers, develop medicines and diagnostic tests to detect and address the malfunctioning in the body. Provides evidence which can support early approval from regulatory bodies. What has changed? From primarily looking at the disease location in the body ... to identifying the root cause of a disease From trial and error ... to putting the uniqueness of patients first From one-size-fits all medicines ... to targeted therapy Traditionally Today Tomorrow Traditionally ... all patients diagnosed with a disease received the same medicine. Although, one-size-fits-all therapies do work for some patients, they can be ineffective and/or even cause side effects for others. Today ... doctors can identify the root causes of disease and therefore better predict how well a patient is going to respond to the treatment. Roche Personalised Healthcare puts the uniqueness of patients first. With the help of sophisticated diagnostic tests and tools, specific genetic defects or other malfunctions can be detected and treated. In oncology, where PHC has advanced fastest we are now aware that there are 250 to 300 types and subtypes of cancer. Tomorrow Do you remember your last visit to the physician? Presumably, the notes were taken down in your physical file and will later on be stored in an archive. This might fundamentally change in the following years, as the digital revolution is at the onset of transforming the healthcare industry. Both research and medical practice are expected to produce*, integrate and use increasingly large data sets on patients, diseases and treatments. By mining this data, researchers and physicians will be able to gain new insights with regard to correlations of patient sub-populations. Hence they will be able better develop, match and continuously optimise treatment for patients. *E.g. clinical trial data Who benefits? Patients Physicians Payers Improved quality of life and lifetime gained Fewer unnecessary treatments, side effects and associated costs Better and more predictable clinical outcomes Increased confidence in treatment and better improvement of outcomes for patients Patients see the benefit of their therapy more clearly, hence they better collaborate Improved evidence simplifying decision-making Optimised use of healthcare resources Improved clinical outcomes Which diseases can today be treated with Roche Personalised Healthcare? Metastatic breast cancer 15 – 20% of patients are HER2-positive Non-small cell lung cancer 10 – 30% of patients are EGFR-positive and more than 8% are ALK-positive Viral infections Hepatitis B, Hepatitis C, HIV Metastatic melanoma ~ 50% of patients are BRAF-positive Stomach cancer 16 – 22% of patients are HER2-positive Targeted treatments are based on the molecular causes of disease. That means they operate based on the presence of biomarkers and through companion diagnostic tests indicating mutations or genetic expressions in the patients' tissue. For example, in the past non-small cell lung cancer (NSCLC) was just diagnosed as NSCLC. Today we know over a dozen gene mutations that can play a role in this type of cancer. Therefore, the detection of biomarkers via diagnostic tests allows for a more targeted treatment patients can benefit from. Mutations potentially causing non-small cell lung cancer. What do people say? The option of targeted treatment gave me hope and a better quality of life. Doretha 'Dee' Burrell Patient Each person’s cancer is different. So are my treatment strategies. Dan Chen Cancer Immunotherapy Franchise Head at Genentech In my view, PHC will be the only way of husbanding our resources in a way that makes good business sense. Prof. Thomas Szucs Insurance Executive It’s exciting to work at the juncture of genomics and medicine. Kim Pelak Data Scientist at Foundation Medicine Thanks to liquid biopsy, we can now detect cancer evidence without surgical intervention. Walther Koch Head of Global Research at Roche Molecular Systems We have made great progress in our understanding of the molecular drivers in cancer and PHC is already helping patients live longer and better lives. Oliver Bleck Franchise Head, Anti-Angiogenisis & Signaling at Roche CEO Severin Schwan on Personalised Healthcare: "We target medicines very specifically to those patient populations who really benefit from the medicine." Vivian L. had metastatic breast cancer and was successfully treated. "When you’re diagnosed with a disease like this you savour every moment of your life. The fact is that medical treatment keeps me alive." With its capabilities in Pharma and Diagnostics, Roche is uniquely positioned to drive Personalised Healthcare. © 2016 F. Hoffmann-La Roche Ltd 25.09.2016 Legal Statement Privacy Policy This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Twitter LinkedIn Facebook YouTube Pinterest